127 related articles for article (PubMed ID: 28236335)
1. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.
Rebulla P; Vaglio S; Beccaria F; Bonfichi M; Carella A; Chiurazzi F; Coluzzi S; Cortelezzi A; Gandini G; Girelli G; Graf M; Isernia P; Marano G; Marconi M; Montemezzi R; Olivero B; Rinaldi M; Salvaneschi L; Scarpato N; Strada P; Milani S; Grazzini G
Transfusion; 2017 May; 57(5):1171-1183. PubMed ID: 28236335
[TBL] [Abstract][Full Text] [Related]
2. Results of clinical effectiveness of conventional versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial.
Koepsell SA; Stolla M; Sedjo RL; Carson J; Knudson M; Cook R; Fasano R; Ngamsuntikul SG; Cohn C; Gorlin J; Delaney M; Slichter S; Ness P; McCullough J
Transfusion; 2024 Mar; 64(3):457-465. PubMed ID: 38314476
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
Mirasol Clinical Evaluation Study Group
Transfusion; 2010 Nov; 50(11):2362-75. PubMed ID: 20492615
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.
Garban F; Guyard A; Labussière H; Bulabois CE; Marchand T; Mounier C; Caillot D; Bay JO; Coiteux V; Schmidt-Tanguy A; Le Niger C; Robin C; Ladaique P; Lapusan S; Deconinck E; Rolland C; Foote AM; François A; Jacquot C; Tardivel R; Tiberghien P; Bosson JL;
JAMA Oncol; 2018 Apr; 4(4):468-475. PubMed ID: 29392283
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system.
Vamvakas EC
Vox Sang; 2012 May; 102(4):302-16. PubMed ID: 21957897
[TBL] [Abstract][Full Text] [Related]
7. Clarify the negatives of the MIRASOL noninferiority trial.
Strauss RG
Transfusion; 2011 Jun; 51(6):1361-2; author reply 1362-4. PubMed ID: 21658043
[No Abstract] [Full Text] [Related]
8. Comparison of transfusion-outcome in patients with massive bleeding receiving pathogen-reduced platelets prepared with two different technologies.
Arcas Otero C; Pereira Saavedra A; Castrillo Fernández A; Vilariño López MD
Transfus Apher Sci; 2022 Jun; 61(3):103359. PubMed ID: 35074272
[TBL] [Abstract][Full Text] [Related]
9. Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial.
Norris PJ; Kaidarova Z; Maiorana E; Milani S; Lebedeva M; Busch MP; Custer B; Rebulla P
Transfusion; 2018 May; 58(5):1210-1217. PubMed ID: 29473173
[TBL] [Abstract][Full Text] [Related]
10. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
11. A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets.
MacLennan S; Harding K; Llewelyn C; Choo L; Bakrania L; Massey E; Stanworth S; Pendry K; Williamson LM
Transfusion; 2015 Aug; 55(8):1856-65; quiz 1855. PubMed ID: 25727713
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial.
van der Meer PF; Ypma PF; van Geloven N; van Hilten JA; van Wordragen-Vlaswinkel RJ; Eissen O; Zwaginga JJ; Trus M; Beckers EAM; Te Boekhorst P; Tinmouth A; Lin Y; Hsia C; Lee D; Norris PJ; Goodrich RP; Brand A; Hervig T; Heddle NM; van der Bom JG; Kerkhoffs JH
Blood; 2018 Jul; 132(2):223-231. PubMed ID: 29773572
[TBL] [Abstract][Full Text] [Related]
13. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial.
Ypma PF; van der Meer PF; Heddle NM; van Hilten JA; Stijnen T; Middelburg RA; Hervig T; van der Bom JG; Brand A; Kerkhoffs JL;
BMJ Open; 2016 Jan; 6(1):e010156. PubMed ID: 26817642
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.
Kaplan A; Lindgren B; Marschner S; Aznar M; Zalba S; Sánchez P; Ayape ML; Olavarría E; Antelo ML
Transfus Apher Sci; 2016 Apr; 54(2):248-52. PubMed ID: 26345109
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial.
Brixner V; Bug G; Pohler P; Krämer D; Metzner B; Voss A; Casper J; Ritter U; Klein S; Alakel N; Peceny R; Derigs HG; Stegelmann F; Wolf M; Schrezenmeier H; Thiele T; Seifried E; Kapels HH; Döscher A; Petershofen EK; Müller TH; Seltsam A
Haematologica; 2021 Apr; 106(4):1086-1096. PubMed ID: 33538149
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
McCullough J; Vesole DH; Benjamin RJ; Slichter SJ; Pineda A; Snyder E; Stadtmauer EA; Lopez-Plaza I; Coutre S; Strauss RG; Goodnough LT; Fridey JL; Raife T; Cable R; Murphy S; Howard F; Davis K; Lin JS; Metzel P; Corash L; Koutsoukos A; Lin L; Buchholz DH; Conlan MG
Blood; 2004 Sep; 104(5):1534-41. PubMed ID: 15138160
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy and safety of pathogen-reduced platelet components: Results of a meta-analysis of randomized controlled trials.
Cid J; Charry P; Lozano M
Vox Sang; 2024 Mar; 119(3):203-211. PubMed ID: 38181391
[TBL] [Abstract][Full Text] [Related]
18. Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.
Infanti L; Stebler C; Job S; Ruesch M; Gratwohl A; Irsch J; Lin L; Buser A
Transfus Apher Sci; 2011 Oct; 45(2):175-81. PubMed ID: 21840762
[TBL] [Abstract][Full Text] [Related]
19. Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period.
Łętowska M; Przybylska Z; Piotrowski D; Lachert E; Rosiek A; Rzymkiewicz L; Cardoso M
Transfusion; 2016 Mar; 56 Suppl 1():S39-44. PubMed ID: 27001360
[TBL] [Abstract][Full Text] [Related]
20. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA
Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
